The nicotinic acetylcholine receptors (nAChRs) and the 5-HT 3 receptors (5-HT 3 Rs) are cation-selective members of the pentameric ligand-gated ion channels (pLGICs), which are oligomeric protein assemblies that convert a chemical signal into an ion flux through postsynaptic membrane. They are critical components for synaptic transmission in the nervous system, and their dysfunction contributes to many neurological disorders. The diverse subunit compositions of pLGICs give rise to complex mechanisms of ligand recognition, channel gating, and ion-selective permeability, which have been demonstrated in numerous electrophysiological and molecular biological studies, and unraveled by progress in studying the structural biology of this protein family. In this review, we discuss recent insights into the structural and functional basis of two cation-selective pLGICs, the nAChR and the 5-HT 3 R, including their subunit compositions, ligand binding, and channel gating mechanisms. We also discuss their relevant pharmacology and drug discovery for treating various neurological disorders. Finally, we review a model of two alternative ion conducting pathways based on the latest 5-HT 3A crystal structure.
Introduction
The nicotinic acetylcholine receptors (nAChRs) and the 5-hydroxytryptamine type 3 receptors (5-HT 3 Rs) are cationselective members of the pentameric ligand-gated ion channels (pLGICs), which also include the anion-selective GABA and glycine receptors, the cation channel homologs in prokaryotes (including the bacterial Erwinia chrysanthemi ligand-gated ion channel (ELIC) and the Gloebacter violaceus ligand-gated ion channel (GLIC)) and the anion-selective homolog in invertebrates (the glutamate-gated chloride channel (GluCl)) ( Figure  1 ).
Both nAChRs and 5-HT 3 Rs comprise five subunits arranged around a central ion-conducting pore that is permeable to cations including Na + , K + and Ca 2+ when the receptors are activated [1] [2] [3] . These receptors exist in different inter-convertible conformational states that are triggered by the binding of agonists, antagonists, or allosteric modulators [4] (Figure 2 ). The nAChRs and 5-HT 3 receptors are expressed throughout the central nervous system (CNS) [5, 6] and peripheral nervous system (PNS) [7] and mediate a variety of physiological functions. The nAChRs are potential therapeutic targets for multiple central nervous system disorders such as schizophrenia, Alzheimer's disease, Parkinson's disease and nicotine addiction [8] [9] [10] [11] . Moreover, ligands that target the 5-HT 3 Rs are powerful therapeutic agents for the control and treatment of drug and alcohol dependence, schizophrenia, anxiety, and cognitive dysfunction, as well as chemotherapy-induced and post-operative nausea and vomiting [12] [13] [14] [15] . As such, both nAChRs and 5-HT 3 Rs have been the targets of drug discovery efforts for many years. Some of these efforts have gone beyond clinical evaluation and led to marketed drugs [16] . A more comprehensive understanding of the connection between the structure and function of these receptors could facilitate ongoing drug discovery efforts. In this review, we summarize the current structural and functional knowledge of the nAChRs and the 5-HT 3 Rs.
Receptor subunits and components
To date, seventeen nAChR subunits and five 5-HT 3 R subunits have been identified. The nAChR subunits include multiple α (α1−α10) and β subunits (β1−β4) as well as δ, γ, and ε subunits, and the 5-HT 3 R subunits include A, B, C, D, and E subtypes [17] . These subunits have been highly conserved through evolution and each single subunit has more than 80% amino acid identity across vertebrate species. The nAChR subunits can be divided into four subfamilies (I-IV) based on similarities in protein sequence, and the classification of 5-HT 3 R subunits is relatively simple [18] (Figure 3 ). The diversity in subunit composition may influence the characteristics of nAChRs and 5-HT 3 Rs, including their agonist sensitivity, channel kinetics, Ca 2+ permeability, assembly, interactions with chaperones, trafficking and cell localization [19] [20] [21] [22] [23] . Muscle-type nAChRs are composed of α1, β1, γ, and δ subunits in a 2:1:1:1 ratio or composed of α1, β1, δ and ε subunits in a 2:1:1:1 ratio. Neuronal-type receptors are homomeric or heteromeric combinations of twelve different nicotinic receptor subunits, α2−α10 and β2−β4, such as (α4) 3 (β2) 2 , (α4) 2 (β2) 3 , or (α7) 5 [24] . A functional 5-HT 3 receptor may be composed of five identical 5-HT 3A subunits (homopentameric) or a mixture of 5-HT 3A and one of the other four 5-HT 3B , 5-HT 3C , 5-HT 3D , and 5-HT 3E subunits (heteropentameric) [25] . The homomeric nAChR and 5-HT 3 Rs have five identical ligand binding sites located at the interface between two adjacent subunits [26] . Each heteromeric nAChR contains two agonist binding sites with different affinities. Although the subunit stoichiometry of the heteromeric 5-HT 3 Rs is not clearly studied, it was demonstrated that agonists bind to an interface between two adjacent 5-HT 3A subunits in the heteromeric 5-HT 3AB receptor [27] , which may explain why the 5-HT 3A subunit is essential to form functional 5-HT 3 receptors. Because the binding sites cooperate, all sites need to be occupied with agonist to fully activate the ion channel. Elucidation of the influence of subunit composition on ligand binding and channel function will be an important topic of future research on these two receptors.
Definition and physiological functions
In the human nervous system, nicotinic cholinergic signals are extended throughout the system, where the neurotransmitter acetylcholine (ACh) plays a key role in activating ligand-gated ion channels, which is one of the most important and oldest modulatory neurotransmitter systems [28] . ACh is synthesized in specific neurons by choline acetyltransferase from choline and acetyl-CoA. The enzyme acetylcholinesterase converts ACh into inactive metabolites choline and acetic acid in the intercellular space. The degradation products can be transported back into the nerve cells by specific transporters [29] . Importantly, ACh is released from presynaptic neurons and binds to the nAChRs that modulate the flow of ions across the (Figure 2 ). In the nervous system, cholinergic stimulation mediated through nAChRs controls pathways such as transmitter release and cell sensitivity, which can influence physiological activity including sleep, anxiety, pain processing and cognitive functions [30] [31] [32] [33] . A net influx of cations through the associated channel pore depolarizes the cell membrane and increases neuronal excitability. In particular, calcium entry through the nAChRs triggers a series of intracellular signaling cascades [23] . On the molecular level, the activation of presynaptic 5-HT 3 Rs also induces Ca 2+ influx and modulates the vesicular release of various neurotransmitters and neuropeptides [34] [35] [36] . The activation of postsynaptic 5-HT 3 Rs leads to depolarization by the opening of a channel permeable to Ca 2+ as well as Na + and K + . On the systemic level, the 5-HT 3 Rs in the CNS are involved in the integration of the vomiting reflex, pain processing, anxiety control and the reward system, while peripheral receptors participate in the regulation of autonomic functions and sensory transmission [37] . 5-HT 3 R agonists lead to unpleasant feelings, such as nausea and anxiety, thus are rarely used clinically. However, 5-HT 3 R antagonists are widely used for relieving chemotherapy-induced vomiting as well as radiotherapyinduced and post-operative nausea and vomiting. The 5-HT 3 Rs also regulate gastrointestinal (GI) functions including secretion and motility, while their antagonists are effective in the management of post-infectious irritable bowel syndrome and severe diarrhea-predominant irritable bowel syndrome, although they present adverse gastrointestinal effects. More recently, involvement of the 5-HT 3 Rs was found in psychiatric indications such as drug addiction, cognitive function, schizophrenia, satiety control, and the regulation of inflammatory and immune responses [38] [39] [40] . The physiological processes regulated by the nAChRs and the 5-HT 3 Rs are dependent on the specific ligand bound [41] . As illustrated in Figure 2 , the binding of exogenous agonists to the orthosteric site substantially influences the transition rates between three distinct functional states of the receptor: the closed, open and desensitized states [42] . The rate constants between different functional states are highly dependent on the specific combination of subunits and the chemical nature of the agonist bound at the receptor [43] . The transition rates between the conformational states can also be modulated by endogenous or exogenous allosteric modulators [44] . Essentially, the conformational states of the receptor influence the activity of the target cells through the selective transportation of Na + , K + , and Ca 2+ into cells to regulate various physiological processes [45] .
Overall structure
With the development of new technologies in structural biology, structural studies of ion channels have been progressing steadily, providing insights into the three-dimensional struc- Figure 4 ). The first high-resolution cryo-EM structure (4 Å) of the nAChR from the Torpedo marmorata electric organ was reported in 2005, revealing important functional and pharmacological characteristics of this receptor [46] . Based on the X-ray structures of the acetylcholine binding protein (AChBP) and the serotonin binding protein (5-HTBP), an atomic model of the extracellular domain (ECD) of nAChR has been available for 15 years [47] [48] [49] . AChBP and 5-HTBP are water-soluble proteins that have a high degree of sequence similarity to the ECD of the nAChR and the 5-HT 3 Rs, respectively. In 2008 and 2009, X-ray structures of two prokaryotic pLGICs, ELIC [50] and GLIC [51] , were determined. Both are cation-selective ion channels that show high sequence and structure similarity to the nAChRs and the 5-HT 3 Rs. In 2011, the first X-ray structure of a eukaryotic pLGIC was determined [52] . The crystal structure of the GluCl from Caenorhabditis elegans revealed an open conformation of the pLGIC. In 2014, two groups presented the X-ray structures of two mammalian pLGICs, the human GABA A β3 receptor [53] and the mouse 5-HT 3A receptor [54] . These two structures offered the latest insights into the signaling mechanisms of pLGICs. Specifically, the serotonin 5-HT 3 R and the nAChR are closest among the pLGICs and show very high sequence similarity ( Figure 5A ), suggesting that they may share structural characteristics and regulatory mechanisms. Notably, both the GluCl and 5-HT 3A structures were determined in complex with an antibody or a nanobody, which facilitates the crystallization of transmembrane channels.
Comparison of the aforementioned structures reveals that the overall structure appears to be conserved among the pLGICs, particularly the eukaryotic cation pLGICs, the nAChRs and the 5-HT 3 Rs. The different nAChR and 5-HT 3 R subunits share a basic scaffold composed of an ECD, a fourtransmembrane helix domain (TMD), an intracellular domain (ICD) between the third and fourth transmembrane helix and a short extracellular C-terminus. The receptors are therefore built from modular units with an extracellular domain containing the agonist/antagonist binding pocket, a transmembrane domain containing the allosteric modulatory sites and a large cytoplasmic domain involved in receptor trafficking and regulation ( Figure 5B and 5C). Comparison of available structures revealed that the overall structure of cation-selective pLGICs (nAChRs and 5-HT 3 Rs) is different from anion-selective pLGICs (GABA A Rs and GlyRs), with the presence of a relatively large ICD that may play an important role in cation conduction.
Extracellular domain and binding pocket
The organization of the ligand binding pocket of the nAChRs and the 5-HT 3 Rs has been confirmed by many structures. A major step toward this achievement was the determination of the high-resolution crystal structures of the soluble proteins that bind ACh or serotonin, AChBP and 5-HTBP, respectively. These soluble proteins share key structural elements with the ECDs of nAChRs and 5-HT 3 Rs, which display similar ligand binding signatures, and their respective structures have become models for the ECDs of the nAChR and the 5-HT 3 R. The 5-HTBP was engineered from the weakly 5-HT-binding AChBP by a series of mutations. Single-point mutations of the nAChR and the 5-HT 3 R are sufficient to switch agonist actions of serotonin and acetylcholine, respectively, to antagonists [55, 56] . These mutations confirm the ligand recognition sites and reveal that the nAChR and the 5-HT 3 R use the same structural elements for ligand binding.
Based on the modeling of the pentameric structure of AChBP, each nAChR ECD monomer consists of an N-terminal α-helix and a core of ten β-strands that form an αβ-sandwich structure. The inner β-sheet is formed by β1, β2, β3, β5, β6 and β8 and the outer β-sheet by β4, β7, β9 and β10. The Nand C-termini are located at the top and bottom of the pentamer fold, respectively. The C-terminus of β10 is connected to the N-terminus of TM1. The linker between strands β6 and β7 forms the signature Cys-loop found in all members of the Cys-loop receptor (CLR) family. This Cys-loop is close to the transmembrane domain and may play a role in the propaga- npg tion of conformational changes from the ECD to the TMD [57] ( Figure 5C ). High resolution crystal structures of AChBPs in complex with several nicotinic receptor ligands revealed the orthosteric binding sites for agonists and antagonists in detail. The ligand binding sites are situated at the interface between two neighboring subunits, the principal (ie, two constant α-subunits) and the complementary non-α subunits ( Figure  6A) . Residues from loops A-C of the principal subunit as well as β-strands D/E and loop F of the complementary subunit contribute to ligand recognition. The key residues involved in ACh binding are Trp86, Tyr93 (loop A), Trp149, Gly153 (loop B), Tyr190, Cys192, Cys193, and Tyr198 (loop C) from the principal subunit, and Trp55, Asp57 (β strand D), Leu109, Arg111, Thr117, Leu119 (β strand E), Asp174, and Glu176 (loop F) from the complementary subunit [58] ( Figure 6A ). Although the subunits of mammalian pLGIC are generally conserved, these pocket amino acids are not identical in nAChRs and 5-HT 3 Rs, providing a basis of their ligand binding selectivity. 
Transmembrane domain and allosteric modulatory sites
The transmembrane domain of the nAChRs and the 5-HT 3 Rs is composed of four helices, TM1 to TM4, which perpendicularly span through the membrane bilayer. The TM1, TM2, and TM3 helices are a closely packed bundle and are ordered in two concentric circles. The assembly of the five TM2 helices forms the inner circle and the ion channel pore, which is an important segment of the ion conduction pathway. Transmembrane helices TM1 and TM3 form the outer circle that stabilizes the pore. TM4, located at the periphery of the transmembrane domain, is relatively loosely packed [59] [60] [61] (Figure 6B ). The transmembrane domains of the nAChRs and the 5-HT 3 Rs contain binding sites for various allosteric modulators. General anesthetics are small hydrophobic compounds that allosterically inhibit the receptors by binding to a small cavity formed by specific residues located between TM3 and TM4. Crystal structures of the GluCl in complex with a hydrophobic ligand enabled visualization of this allosteric binding site. These allosteric modulators act by binding to regions called allosteric sites, which are separate from the ACh/ serotonin binding sites (orthosteric sites) ( Figure 6B ). The allosteric modulators have either positive (positive allosteric modulators, PAMs) or negative (negative allosteric modulators, NAMs) effects [62] . PAMs/NAMs typically exhibit little intrinsic activity but provide selective potentiation/inhibition of physiological activity without directly interfering with the ongoing signaling processes. Ivermectin, 5-hydroxyindole, NS-1738, SB-206553 and PNU-120596 have been reported to function as PAMs at the nAChRs [63] . The development of PAMs is of great significance, as they may effectively avoid receptor desensitization processes.
Channel activation
The overall architecture of the channel complex assembly reveals that the ligand binding site in ECD is far above the channel pore in the TMD region (Figure 4) . The mechanism of how ligand binding at the ECD can control (by gating) the opening and closing of the distal channel pore at the TMD is very intriguing. At their resting states, the channels of the nAChRs and the 5-HT 3 Rs are closed. The binding of agonist to the ECD triggers rapid conformational changes, which leads to the opening of the transmembrane pore, a process referred to as gating isomerization.
The crystal structures of a chimeric α7 nicotinic recep- 
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Acta Pharmacologica Sinica npg tor ECD with its agonist epibatidine [64] and its antagonist α-bungarotoxin [65] enabled observation of this process. Structural comparison of the agonist-and antagonist-bound conformations revealed a large movement of loop C, which was also observed in a similar comparison of the agonist-and antagonist-bound 5-HTBP structures [66] . By further investigation of these structures, a twisting and blooming model was initially suggested to be directly involved in ion channel activation ( Figure 7A ). The relatively small conformational changes at the ligand binding site suggest a highly efficient gating mechanism.
Structures of the open state GLIC and the closed state ELIC elucidate how the conformational changes induced by agonist binding are propagated from the ECD to the TMD ( Figure   Figure ). The proposed model of gating is a stepwise isomerization process that starts from the orthosteric binding site (loops A, B, and C) ( Figure 7C ), then propagates to the ECD/TMD interface (β1-β2 loop and Cys-loop) via a rigid-body rearrangement of the extracellular β-sandwiches, which in turn induces outward movement of the loop between transmembrane helices TM2 and TM3, ultimately resulting in the opening of the gate that is formed by the TM2 helix ( Figure 7D ). This structural rearrangement was best described as a concerted opposite-twist rotation of the ECD relative to the TMD around the five-fold symmetry axis. In 2011 and 2014, two structures of the C. elegans GluCl were published. One structure is in complex with the allosteric partial agonist ivermectin, which provided insights into the structure of a potentially open state, and the other is the apo state, a 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)-bound conformation [67] . These two structures of eukaryotic Cys-loop receptors further answered questions regarding the mechanism of channel opening and closing. The TM2-TM3 loop can shift away from the ion channel pore, as visualized by the movement of Pro268 from the TM2-TM3 loop passing beneath Val45 on the β1-β2 loop. The closed pore is most constricted at Leu254 on TM2, suggesting that Leu254 forms the shut gate of the ion channel pore ( Figure 8A ). Further- [68] . (B) Sequence alignment of the Cys-loop receptors. Key residues are indicated by the arrow. GluCl: C. elegans GluCl α; GlyR: human glycine α1; GABAR: human GABAβ3; 5-HT 3 R: mouse 5-HT 3A ; and nAChR: human nAChR α7.
more, Pro268 and Leu254 are strictly conserved throughout the family of Cys-loop receptors ( Figure 8B ), and they could play a similar role in the opening and closing of nAChRs and 5-HT 3 Rs. Taken together, the available structures present a common ligand gating mechanism, where ligand binding at the ECD induces a stepwise isomerization of the subunit interface, which is then propagated to the ECD-TMD interface, resulting in tilting of the TM2 helix that leads to the opening of the channel pore (Figure 7) . Interestingly, the allosteric ligand binding site is located in the TMD that is close to the channel pore but far from the ligand binding site in the ECD. We speculate that PAMs and NAMs modulate the channel activities by reducing (PAM) or increasing (NAM) the energy barrier of channel opening.
Cation selectivity and ion conduction in the ICD
The cation selectivity of nAChRs and 5-HT 3 Rs is determined by the charge properties along the ion permeation pathway ( Figure 9A ). The width of the extracellular vestibule is approximately 20 Å, which is appropriate for electrostatic interactions between the charged groups lining the vestibule and for cations to pass through. The charge below the conserved constriction (D105 in the mouse 5-HT 3A receptor) is predominantly negative, thus providing an environment to stabilize cations and increase the local concentrations of cations within the lower part of the ECD vestibule. From the bottom of the ECD, cations enter the pore lined by the TM2 helices, and the residues that form the pore lumen surface are almost identical in nAChRs and 5-HT 3 Rs ( Figure 9B ). The upper portion of the pore is a hydrophobic constriction that may serve as the channel gate, while the lower half contains two polar rings that are negatively charged. The negatively charged residues at the bottom of the transmembrane pore may facilitate cations entry into the intracellular vestibule, which has been identified as a major determinant of ionic selectivity and conductance [68] [69] [70] ( Figure 9B ).
The intracellular vestibule is lined by the post-TM3 loop and the C-terminal amphipathic membrane-associated (MA) helices, which were revealed in the EM structure of the Torpedo acetylcholine receptor and the X-ray structure of the mouse serotonin 5-HT 3A receptor. The structure of the Torpedo acetylcholine receptor revealed that there are solvent-exposed channels in the upper part of the MA helices for ion exit and entry. The corresponding solvent-exposed channels appear to be blocked by the post-TM3 loops in the mouse serotonin 5-HT 3A receptor structure. Moreover, in the 5-HT 3A structure, the lower part of the MA helical bundle forms a central channel that is too narrow for ions to pass through unless conformational changes occur. To confirm the exit or entry of ions in the ICD, the conformation of intact receptors in the active state requires further investigation. However, two possible pathways for ion conductance in the ICD are shown in Figure 10 . Mutagenesis studies support that the upper channels, not the lower MA helix, are involved in ion conductance [71] .
Diseases and drug discovery
In parallel with advances in our understanding of the pharmacology of nAChRs and 5-HT 3 Rs, there has been an increasing interest in these receptors as potential drug targets for a number of psychiatric, neurological, and peripheral disorders [72] ( Table 1) . During the past 10 years, a growing number of [86] . In most cases, these compounds have been designed to be agonists, antagonists, or allosteric modulators for treating a specific disease. The main obstacles in the development of new compounds are unsatisfactory clinical efficacy and a high incidence of adverse events with a narrow therapeutic window. The most common side effects associated with nAChR and 5-HT 3 R ligands occur in the gastrointes- Cytisine agonist Smoking cessation Marketed [74] Bupropion antagonist Smoking cessation Marketed [75] Varenicline agonist Smoking cessation Marketed [76] CP-601927 agonist Smoking cessation Phase 2 [77] Pozanicline agonist ADHD Phase 3 [78] Sofinicline agonist ADHD Phase 2 [79] Altinicline agonist Parkinson Phase 2 [80] GTS-21 antagonist Alzheimer Phase 2 [81] 5-HT 3 R Compound Classification Indications Development status Reference Alosetron antagonist IBS Marketed [82] Granisetron antagonist Antiemetic Marketed [83] Tropisetron antagonist Antiemetic Marketed [84] Ondansetron antagonist Antiemetic Marketed [85] Metoclopramide antagonist Antiemetic Marketed [85] ADHD, attention deficit hyperactivity disorder; IBS, irritable bowel syndrome. Further structural studies of the nAChR and the 5-HT 3 R will enhance the discovery of small molecule modulators of these two important receptors for therapeutic purposes.
Conclusions and future directions
In the past few decades, the nAChRs and the 5-HT 3 Rs have been a focus of intense research. These efforts have greatly increased our understanding of the structural and functional basis of these two important ion channels, which is predominantly a result of technological advances in high-throughput screening and crystallization. Significant progress has also been made in recent years on receptor expression, distribution, and physiological function. However, the molecular mechanisms of cation selectivity, channel gating and interaction with downstream effector proteins remain to be elucidated through the determination and analysis of high resolution structures of these two channels in various conformational states. Additionally, the nAChRs and the 5-HT 3 Rs are implicated in a range of neurological and psychiatric diseases. Significant drug discovery efforts have been devoted to these two receptors and several promising ligands targeting these two receptors have been developed over the past few years. However, the discovery of potent ligands that interact more selectively with the nAChRs and the 5-HT 3 Rs and display minimal or no side effects is urgent. To avoid receptor desensitization and to increase ligand efficacy and selectivity, the development of PAMs has garnered significant interest.
Taken together, the structural information of cation-selective pentameric ligand-gated ion channels has been steadily improved because of the increasing availability of relevant structures over the past decade. These advancements have also led to a better understanding of the disorders and physiological functions associated with nAChRs and 5-HT 3 Rs, and they have started to provide a rational basis for ligand design and drug discovery. With recent technological breakthroughs in structure determination by cryo-EM and femtosecond X-ray laser, one would expect that structural information of these two receptors in various functional states (eg, closed and open states) will provide direct mechanisms of ligand gating and activation and further promote structure-based design of specific ligands to modulate their physiological function and modify the disease states. The recent expression and purification of the nAChR and the human 5-HT 3A receptor will further facilitate the structural studies of these two receptors in various conformational states [87, 88] .
